Company insight
The new generation of platform autoinjectors
An ongoing challenge for manufacturers of drug delivery devices is to produce products that can meet the pace and challenges of pharmaceutical innovation. Platform autoinjectors are already flexible by definition, but new formulations and technology demand increased sophistication in drug delivery. Owen Mumford Pharmaceutical Services’ latest platform disposable autoinjector, Aidaptus, was designed to offer next-generation benefits of flexibility and versatility, while continuing to accommodate the needs of target user groups.
ince changes to drug volume and viscosity are typically made during the development and life-cycle management process, the selected delivery device should ideally be able to adapt to these modifications to facilitate an efficient journey through the clinical trial phases – and ultimately to market. The Aidaptus autoinjector is designed to give pharmaceutical companies the freedom to modify and optimise drug volumes and create new formulations, without needing to switch to a different device or requiring multiple component changes each time.
S
The autoinjector has a self-adjusting plunger, which means that a range of syringe fill volume options are possible without any changes to the device and with no change in parts. It is also compatible with either a 1mL or 2.25mL prefilled syringe, with a minimal number of change parts, while maintaining its small, discreet size (162mm x 18mm). Both vented and vacuum filling are possible, allowing for a choice of contract filling partners.
container closure integrity (CCI) due to changes in external pressure.
Two-step delivery
As a platform product, Aidaptus has been designed for use with patients with different levels and types of physical impairments and cognitive abilities, as well as a range of ages, factoring in the whole injection experience. Needle insertion and dose delivery takes place in two phases. Pressure on the skin automatically activates needle insertion; once this is completed the drug delivery phase then commences. The resulting injection experience is smooth and consistent.
This feature also neatly addresses other common issues with some autoinjectors. Firstly, two-step delivery helps to ensure the full dose is delivered. Secondly, it helps to prevent the drug from spilling before the injection is completed. And thirdly, it reduces the likelihood of the syringe breaking. Typically, a single strong spring is used to deploy both the needle for skin insertion and the plunger
“Aidaptus has been designed for use with patients with different levels and types of physical impairments and cognitive abilities, as well as a range of ages, factoring in the whole injection experience.”
Aidaptus’ self-adjusting plunger has an additional benefit: its unique patented design limits the potential backward movement of the stopper in the syringe barrel during transit from factory to patient, helping to prevent breaches of
18
for dose delivery, and the resulting force can lead to syringe breakage.
Audio-visual notifications Patients sometimes remove their auto- injection from the injection site too early
in the administration process, resulting in a ‘wet injection’, where the full dose is not delivered.
Before injection, Aidaptus users can easily see the drug through the large window, and check drug clarity and colour. They are notified at the beginning and end of their injection with audible clicks, and they can also check for the presence of the bright yellow plunger rod, which is clearly visible in the viewing window once the dose is completed. Aidaptus’ design keeps the needle hidden before, during and after use, a feature which particularly benefits patients with needle-phobia. Once injection is complete, the safety shroud locks in place so that the needle is not exposed to the user before disposal into a Sharps container, minimising the risk of injury.
Future innovation
The pharmaceutical and drug delivery industries are continually innovating to further improve the patient experience and treatment outcomes, and Aidaptus can accommodate some of these new solutions. One area for improvement is label technology, such as new surface finishes and textures, which aid grip and handling. Another is digitalisation of medical devices, and so integrated Near Field Communication (NFC) could also be included in the product to enable connectivity options. Companies can select two presentations for Aidaptus: a traditional opaque moulded body, or a transparent body and over wrap, which can be customised as required. ●
www.ompharmservices.com/ aidaptus
World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
